the short version
the middle of the 13 companies in the API and contract group i track is 9 points ahead of the NIFTY 500 in three months: up 2.6% while the index fell 6.2% (30 jul to 30 oct 2026)
four big jumps came on earnings call days. the first four in my data with july to september results rose 12% to 17% on those days, though i can’t say results explain all of it
the worry: 3 companies blamed timing for at least part of their fall. their september 2026 quarter numbers weren’t in my data as of 1 nov 2026
one thing before we dig in.
i do visual breakdowns of indian companies and sectors so the business is easy to see.
as a free subscriber, you get full support for any question on the indian stock market. charts, fundamentals, what a company is doing, anything you want to understand. i research and answer educationally.
no financial advice. just education.
ask anytime in the Sectoralpha Ask chat.
seven pharma API and contract stocks in India: five years against the NIFTY 500
by my math, the middle of seven companies from the API and contract group i track rose 89.9% from 29 oct 2021 to 30 oct 2026, and the NIFTY 500 rose 45.1%. those seven of the 13 have prices in my data for the whole stretch, and 29 oct 2021 is simply where this chart starts. the range is the real story: Neuland up 1,080%, Hikal down 63%.
why this pharma API and CRAMS group is beating the NIFTY 500: three numbers
these stocks are ahead partly because the index fell, and four of them jumped on their earnings call days. the middle of the 13 is 9 points ahead: up 2.6% while the index fell 6.2%. the first four in my data with september 2026 quarter results jumped 12% to 17% on call day. three more still have to turn late orders into sales.
what is API and CRAMS in pharma: the part of a pill that works
API means active ingredient, the part of a pill that actually treats you. the companies here make that ingredient and sell it to drug companies, or do the research and manufacturing for them on contract. that second job is CRAMS, contract research and manufacturing services. you’ll rarely see their names on a medicine box.
CDMO and API companies in India: the 13 in the group i track
i track these 13 in one API and contract group, and they do three kinds of work. they aren’t all of India’s API makers: Laurus Labs sits outside this group. CDMO means a contract maker. the sorting is mine. Windlas and Innova make finished medicines mostly on contract. OneSource fills and packs injection pens for copies of semaglutide, the weight-loss drug.
pharma API and contract group share price: 10 of these 13 beat the NIFTY 500 in three months
i count 10 of the 13 in this group beating the NIFTY 500 from 30 jul to 30 oct 2026, and the middle one, Neuland, rose just 2.6%. so most of that 9 point lead is the index falling 6.2%. Divi’s rose 24.8%. Dishman fell 21.7%. a sector average would hide that gap, so every name is on the card.
Divi’s Laboratories share price rose 24.8%: profit came first
Divi’s profit after tax went from ₹545 cr to ₹902 cr in april to june 2026, and its share rose the most of the 13 in this group. part of that isn’t pure growth. about 90% of the main company’s sales go abroad, so the exchange rate moves its rupee numbers. at steady exchange rates those sales grew 10%, its director Nilima Divi said.
Divi’s margin rose from ₹30 to ₹41 per ₹100, and an analyst questioned it
a fuller godown may explain part of Divi’s jump in margin, an analyst suggested on its call. stock rose from ₹3,954 cr to ₹4,413 cr. his sum, with the stock build aside, gave ₹28 to ₹30 of operating profit per ₹100 of sales, against the ₹41 Divi’s showed. Divi’s pointed to more production and dearer materials, and gave no figure of its own.
Neuland Laboratories: about three medicines drive the business
Neuland’s profit went from ₹14 cr a year earlier to ₹147 cr in april to june 2026, and its CEO says about three medicines really drive the business. sales went from ₹293 cr to ₹642 cr over the same year. he warned of “certain lumpiness” but said there’s “nothing which is like a one-off”. the share rose only 2.6%, and i can’t say why.
what is destocking in pharma: why a supplier’s sales can fall
destocking means a drug company uses up what it holds before it orders again, and the supplier’s sales drop meanwhile. think of a chemist with a full shelf. he doesn’t order more that month, even if customers keep coming. Blue Jet said one customer did this over several quarters before supply restarted.
why Anthem Biosciences sales fell from ₹540 cr to ₹418 cr
Anthem’s sales fell from ₹540 cr to ₹418 cr in april to june 2026, and its head put it down to delivery timing. asked why customers generally put off deliveries, he described this, for when a medicine sells slower than planned in some market. its share still rose 5.7% in the three months to 30 oct 2026. i can’t fully explain that.
Blue Jet, Dishman and Anthem: three late orders, and when each should land
three companies blamed timing for at least part of their fall, and Blue Jet’s late goods should count first, in july to september 2026. short containers left ₹30 cr more in transit than on 31 mar 2026, it said. Dishman said one order moved to its second half. Anthem expects more deliveries then too, which i read as oct 2026 to mar 2027.
Acutaas, OneSource, Piramal Pharma and Syngene jumped on their september quarter call days
the four that held calls on 27 and 28 oct 2026 jumped 12% to 17% on those days. the index barely moved on either day. Syngene is the odd one: ₹32 cr of profit against ₹67 cr a year earlier, and it still rose 12.2%. Divi’s rose 5.0% on 27 oct with no results in my data as of 1 nov, so results aren’t the whole story.
why Sai Life’s CEO says drug companies are giving India more contract work
Sai Life’s CEO says drug companies are making India a bigger part of how they spread their risk. that’s a company talking about its own market, so treat it as a claim. what i can check: Sai Life’s research sales grew 26% in the june 2026 quarter, its manufacturing 6%, and its share rose 18.4% in three months.
seven pharma API and contract companies: profits fell by a third, then took until 2026 to recover
by my sum, seven of these 13 companies made ₹3,709 cr in the year to march 2022, ₹2,434 cr two years later, and ₹3,719 cr in the year to march 2026. four years to get back. Divi’s is most of that, and at ₹2,568 cr it’s still below its ₹2,960 cr of 2022. in this group, a great year isn’t proof of the next one.
did these pharma API managements deliver? four promises moved in 2026
four promises in this group moved during 2026, so i’d test the late-order story hard. Anthem said restocking had begun, then sales fell on “timing shifts”. Dishman’s 22% to 23% margin target came with a wait-a-quarter caveat, then became “similar to what we did last year”. Hikal’s US regulator fix and Neuland’s plant date slipped too.
what to check in these pharma API results for july to september 2026
three checks will show whether those late orders turn into sales. Blue Jet’s ₹30 cr should show up first. Anthem sold ₹423 cr and ₹611 cr in the same two quarters a year earlier, so it needs more than ₹1,034 cr to beat last year, and ₹1,156 cr to win back the ₹122 cr fall. these are my tests, not company targets.
got a question on this one, or anything else about the indian market?
as a free subscriber you’ve got full educational support in the Ask chat. drop it there. i answer every query. no financial advice.
sectoralpha.in/sectors/pharma-api-crams
— Roshan, Sector Alpha